CUL3 and cancer: Likewise, NAcM-OPT, an orally bioavailable inhibitor with satisfactory solubility and permeability, selectively decreases CUL1 and CUL3 neddylation levels and restrains cancer hallmarks in the squamous cell carcinoma line [132].